AU2005202728A1 - Sustained-release formulations for treating CNS-mediated disorders - Google Patents
Sustained-release formulations for treating CNS-mediated disorders Download PDFInfo
- Publication number
- AU2005202728A1 AU2005202728A1 AU2005202728A AU2005202728A AU2005202728A1 AU 2005202728 A1 AU2005202728 A1 AU 2005202728A1 AU 2005202728 A AU2005202728 A AU 2005202728A AU 2005202728 A AU2005202728 A AU 2005202728A AU 2005202728 A1 AU2005202728 A1 AU 2005202728A1
- Authority
- AU
- Australia
- Prior art keywords
- active compound
- composition
- release
- sustained
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims description 211
- 238000009472 formulation Methods 0.000 title claims description 99
- 238000013268 sustained release Methods 0.000 title claims description 74
- 239000012730 sustained-release form Substances 0.000 title claims description 73
- 230000001404 mediated effect Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 103
- 239000003814 drug Substances 0.000 claims description 103
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 claims description 65
- 238000000576 coating method Methods 0.000 claims description 42
- 239000011248 coating agent Substances 0.000 claims description 39
- 239000011159 matrix material Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 206010010904 Convulsion Diseases 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 28
- 239000007888 film coating Substances 0.000 claims description 26
- 238000009501 film coating Methods 0.000 claims description 26
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 23
- 239000003349 gelling agent Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 15
- 239000001856 Ethyl cellulose Substances 0.000 claims description 14
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 14
- 229920001249 ethyl cellulose Polymers 0.000 claims description 14
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 13
- 230000007170 pathology Effects 0.000 claims description 13
- 208000018198 spasticity Diseases 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 12
- 208000019022 Mood disease Diseases 0.000 claims description 11
- 201000009032 substance abuse Diseases 0.000 claims description 11
- 231100000736 substance abuse Toxicity 0.000 claims description 11
- 208000011117 substance-related disease Diseases 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- 235000019788 craving Nutrition 0.000 claims description 10
- 230000002490 cerebral effect Effects 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 8
- 206010038743 Restlessness Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 230000036461 convulsion Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 6
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 99
- 239000003826 tablet Substances 0.000 description 43
- 238000004090 dissolution Methods 0.000 description 27
- 210000003169 central nervous system Anatomy 0.000 description 21
- -1 isovaleramide Chemical class 0.000 description 18
- 230000001535 kindling effect Effects 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 16
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 16
- 206010015037 epilepsy Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000001961 anticonvulsive agent Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- 150000001408 amides Chemical class 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001773 anti-convulsant effect Effects 0.000 description 6
- 229960003965 antiepileptics Drugs 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000007939 sustained release tablet Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 229960003920 cocaine Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000007941 film coated tablet Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002059 anti-epileptogenic effect Effects 0.000 description 4
- 229940125681 anticonvulsant agent Drugs 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 235000013773 glyceryl triacetate Nutrition 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960002622 triacetin Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000017194 Affective disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000002920 convulsive effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 229920001600 hydrophobic polymer Polymers 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940099367 lanolin alcohols Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 229940042472 mineral oil Drugs 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004274 stearic acid Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940122459 Glutamate antagonist Drugs 0.000 description 2
- 102000011714 Glycine Receptors Human genes 0.000 description 2
- 108010076533 Glycine Receptors Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 206010033864 Paranoia Diseases 0.000 description 2
- 208000027099 Paranoid disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009539 inhibitory neurotransmission Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 208000005809 status epilepticus Diseases 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229960005318 vigabatrin Drugs 0.000 description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- QHNHAWNULKRVMJ-UHFFFAOYSA-N 3-hydroxy-3-methylbutanamide Chemical compound CC(C)(O)CC(N)=O QHNHAWNULKRVMJ-UHFFFAOYSA-N 0.000 description 1
- SIMLCFANWCDGAF-UHFFFAOYSA-N 3-methylpentanamide Chemical compound CCC(C)CC(N)=O SIMLCFANWCDGAF-UHFFFAOYSA-N 0.000 description 1
- 239000002999 4 aminobutyrate aminotransferase inhibitor Substances 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000024255 Audiogenic seizures Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 230000009508 GABAergic inhibition Effects 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940127427 Glycine Agonists Drugs 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010056344 Menstrual discomfort Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 241000792902 Valerianaceae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- RKCHCKMAQPJXBM-UHFFFAOYSA-N ammonium isovalerate Chemical compound N.CC(C)CC(O)=O RKCHCKMAQPJXBM-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000032356 cisplatin-induced susceptibility to hearing loss Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 208000004206 drug-induced akathisia Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003445 gaba agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OVPLZYJGTGDFNB-UHFFFAOYSA-N propan-2-yl carbamate Chemical compound CC(C)OC(N)=O OVPLZYJGTGDFNB-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 201000005070 reflex epilepsy Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000009494 specialized coating Methods 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical class [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 238000012108 two-stage analysis Methods 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant(s): NPS Pharmaceuticals, Inc.
Invention Title: SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS- MEDIATED DISORDERS The following statement is a full description of this invention, including the best method of performing it known to me/us: SSUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED
SDISORDERS
CI Cross Reference to Related Application 0 This application is divided from earlier application CI number 19695/01 dated 19 October 2000.
(C FIELD OF THE INVENTION SThis invention relates to the effective treatment of pathological conditions, such as convulsions, bipolar affective disorder, migraine, anxiety and spasticity, the symptoms of which are alleviated by a modulation of activity in the central nervous system (CNS), without producing undesirable excessive sedation or muscle weakness. More particularly, the invention relates to the preparation and use of oral sustained-release pharmaceutical formulations of isovaleramide and related compounds for the treatment of patients suffering from such conditions.
BACKGROUND OF THE INVENTION A number of pathological conditions are characterized by a profound aberration in the normal function of the CNS. Such conditions include, for example, epilepsy, stroke, bipolar affective disorder, migraine, anxiety, spasticity, spinal cord injury, chronic neurodegenerative disorder and diseases such as Parkinson's disease, Huntington's disease, and Alzheimer's disease. At the clinical level, these conditions usually respond only to pharmacologic intervention with compounds or substances that possess significant activity at the level of the CNS.
Isovaleramide, isovaleric acid and related compounds have been described for treating abnormalities of the CNS, such as epilepsy. These compounds provide a therapeutic 1 H:\marieag\Keep\speci\P7359div.doc22/06/05 approach by effecting a modulation of CNS activity without
(N
Sproducing excessive sedation, muscle weakness, fatigue, ;Z teratogencity or hepatoxicity.
c-i It has been discovered herein that orally administered isovalermide has a short half-life in humans. In the absence of an approach to reduce the rate of uptake of 00 C-i drug following administration, the short half-life C.q requires that isovaleramide be administered frequently to C) sustain a therapeutic concentration of the drug without it adverse effects. Frequent dosing schedules increase costs 0 and raise concerns of patient compliance. Thus, it would be desirable to have a sustained-release formulation of isovaleramide, and related compounds that can be administered on a once or twice per day schedule for the effective treatment of epilepsy and other pathological conditions of the CNS.
SUMMARY OF THE INVENTION Accordingly, the present invention addresses the provision of a composition comprising a sustained-release drug formulation for sustained delivery of isovaleramide and related compounds for the treatment of various pathologies by effecting a modulation of CNS activity without producing excessive sedation, muscle weakness, fatigue, teratogenicity or hepatotoxicity. Such composition is useful for the treatment of convulsions, spasticity, affective mood disorder, neuropathic pain syndrome, migraine and other headache pathologies, restlessness syndrome, movement disorder, substance abuse/craving, cerebral trauma and anxiety-related disorders such as restlessness, nervousness, inability to concentrate, over-aggressiveness, irritability, and insomnia as well as symptoms of smoking cessation, treatment of alcoholism and other substance abuse, premenstrual syndrome, menstrual discomfort, and hyperexcitability in children.
2 H:\marieag\Keep\Speci\P57359div.doc22/06/05 Accordingly, there has been provided, according Sto one aspect of the present invention, an oral sustainedrelease pharmaceutical composition, comprising a matrix C9 comprising a therapeutically effective amount of an 0 active compound; and CA( a gelling agent, CA( wherein the amount of said active compound represents Cg about 40-70% by weight of the composition, and wherein said active compound is isovaleramide. Upon oral Sadministration, in one embodiment, the sustained release formulation releases the active compound over a period of at least 8 to 12 2a H:\marieag\Keep\Speci\P57359div.doc22/06/05 hours With such a formulation, only two administrations of drug need to ;Z be given each day.
In accordance with another embodiment of the present invention, the sustained-release composition comprises a matrix, wherein the matrix comprises 00 5 a gelling agent that dissolves slowly and/or resists hydration. In one embodiment, the gelling agent is xanthan gum. In another embodiment, the active compound is dispersed in the matrix.
In accordance with another embodiment of the present invention, the sustained-release composition comprises a film-coating that retards access of liquids to the active compound and/or retards release of the active compound through the film-coating.
In accordance with yet another embodiment of the present invention, the sustained-release composition comprises one or more excipients that assist in formulation.
In accordance with still another embodiment of the present invention, the sustained-release composition comprises a core wherein the core comprises a compressed mixture of the therapeutically effective unit dose of the active compound and a matrix material, and a film-coating around the core. In another embodiment, the matrix material dissolves slowly and/or resists hydration, while in another embodiment, the matrix material is xanthan gum.
In accordance with another embodiment, the composition fuirther comprises one or more excipients to assist in formulation.
In accordance with yet another embodiment, the film coating comprises a polymeric coating material. In a fuirther embodiment., the polymeric material comprises a mixture of ethyl cellulose and hydroxypropyl methylcellulose, and in another embodiment, further comprises a plasticizer.
In accordance with still yet another embodiment, the sustained-release composition is in the form -of a tablet, capsule, or multiparticulate composition.
In accordance with another aspect of the present invention, a process is provided for producing the sustained-release formulations described above.
I
In accordance with yet another aspect of the present
(N
Sinvention, methods are provided for treating CNS mediated pathologies and conditions by administering the oral (1 sustained-release compositions described above.
In yet another aspect of the present invention, there is provided use of the oral sustained-release
OO
pharmaceutical composition described above to treat CNS C-i mediated pathologies and conditions. In a further aspect, there is provided use of the oral sustained-release pharmaceutical composition described above in the O preparation of a medicament for treating CNS mediated pathologies and conditions.
Other features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS.
Figures la and lb depict the structures of compounds, including isovaleramide, capable of inducing a modulation of the central nervous system.
Figure 2 portrays a 24-hour dissolution profile of film-coated sustained-release tablets containing 400 mg of isovaleramide (Formulation II, Example Dissolution is performed in two stage media essentially as described in Example 2.1 using simulated gastric fluid without enzymes (SGF) followed by simulated intestinal fluid without enzymes (SIF). Dissolution in SGF and SIF alone also is analyzed. Percent of drug released as determined by HPLC label claim) is plotted on the Y axis versus time (hours) on the X axis. At 16 hours, over 75% of the H: \marieag\Keep\Speci\P57359div.doc22/o6/o5 drug is released under the two stage analysis. Drug Srelease efficiency is greater in SIF as compared to SGF as shown by the individual dissolution profiles.
CO( Figure 3 portrays a 24-hour dissolution profile of film-coated sustained-release tablets containing 600 mg of isovaleramide (Formulation III, Example The CA( dissolution assay and subsequent analysis is performed as Cl described in Example 3.1. At 16 hours, over 80% of the Cq drug is released under the two stage media analysis. Drug release rate is similar for SIF and SGF as shown by the Sindividual dissolution profiles.
H: \marieag\Keep\Speci\57359div.doc22/6/o5 Figure 4 portrays a 24-hour dissolution profile of film-coated ;Z multiparticulate composition formulations containing isovaleramide (Example cN, The dissolution assay and subsequent analysis is performed as described in Example 3.2.
00 5 Figure 5 portrays a 2 4-hour dissolution profile of the 6 and 8 filmcoated multiparticulate composition formulations containing isovaleramide. At 16 hours, approximately 80% of the drug is released. Drug release rate is similar for SIF and SGF as shown by the individual dissolution profiles.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS
1.
OVERVIEW
Isovaleric acid and its pharmaceutically acceptable salts, amides such as isovaleramide, alcohol esters and structurally related compounds effect a modulation of CNS activity and are useful for treating epilepsy and a variety of other CNS disorders. As described below (Example orally administered isovaleramide is readily absorbed from the gastrointestinal tract and rapidly eliminated in human subjects, exhibiting a half-life of about 2.5 hours for doses ranging from 100 to 1600 mg. These characteristics are inconvenient for using isovaleramide for oral treatment of CNS disorders because frequent dosing is required to maintain a therapeutic drug level, which could create problems with patient compliance and costs.
In response to this need, the present invention provides sustainedrelease compositions of isovaleramide and related compounds. The formulations disclosed herein are designed to deliver a specific amount of drug over a specific course of time to achieve a therapeutic plasma drug concentration, while minimizing peak to trough differences that occur in vivo.
This is achieved despite the fact that the drug is very water soluble.
"Sustained Release" as used herein, means the release of an active compound whereby the level of active compound available to the host is maintained at some level over a period of time. This is distinguished from "controlled release" which typically is broadly defined to include instantaneous release, delayed release and sustained release concepts. "Instantaneous release" refers to immediate release to the biosystem of the host while "delayed release" means the active ingredient is not made available to the host until 0, 5 some time delay after administration. Although the compositions of the present invention are designed to achieve sustained release of the active compounds of the composition, instantaneous release and delayed release properties also can be designed into the instant compositions without departing from the spirit of cthe invention.
2. PREPARATION OF SUSTAINED-RELEASE
FORMULATIONS
Identification of active compounds Active compounds for treating CNS disorders include isovaleric acid, a pharmaceutically acceptable salt of isovaleric acid, a pharmaceutically acceptable ester of isovaleric acid, a pharmaceutically acceptable amide of isovaleric acid, and related compounds as described in WO 98/08498AI and U.S. application serial no. 09/258,882 (pending). As described therein, isovaleric acid is available from extracts of the rhizomes and roots of Valeriana spp. (common name: valerian; family Valerianaceae) and ammonium isovalerate and isovaleramide are produced in ammoniated tinctures of the extracts.
Generally, esters of isovaleric acid are expected to be hydrolyzed in vivo by ubiquitous esterase enzymes, thereby releasing isovaleric acid and the constituent alcohol. In addition to sovaleramide, various N-substituted amides of isovaleric acid also are described in WO 9 8/08498AI and U.S. application serial no. 09/258,882 Active compounds also include compounds structurally similarity to isovaleramide and which share similar pharmacological activities. These compounds generally share the common structure: C-I2 00
CR
3 Where A C~HorOH, X CR2,
CHCII
3 c(Cffi) 2 or Z H, CH2COZH, or CH2CoNffi The structures of these compounds are shown in Figures la and lb and include substituted isovaleramides such as 2 -methylisovaleram~ide, 3methylisovaleraide, 2 2 -dimethYlisovaleramije, 2,-iehlsoaeai 4 -methylisovaleramide, 2 4 -dimethylisovaleramide, 3,-iehlsoaeai 2 t 2 ,4-trimethy1isovalerami~de, 3-hydroxyisovaleramide, 4h~rxiovlrmd,4hYdroxy-mehlisovaleyrajid 2h~rxioaeaie and 2,-iehln-uyaie For'each of these compounds that contains one or more asynmmetic centers, the present invention specifically includes each of the Possible enantiomneric: or diastereomeric forms of the compound.
N,N-Diethyl isovaleranijd (rValyl"), although purported to possess CNS depressant (sedative) activity, recently has been shown to possess
CNS
stimulant (convulsant) properties patent No. 5,506,268 and PCT application WO 94/28,888). .An ami .de of isovaleric acid with p-anhinophenol1 also can be prepared using standard methods to provide a compound, "isovaleraminophen, which is related structurally to the drug acetamiinophen (Tylenol's). In a manner analogous to that of the isovalerate esters, these.
substituted amides should be hydrolyzed in vivo (in this case, via hepatic ;Zarnidase enzymes), releasing isovaleramfide or isovaleric acid N In addition to the amnide compounds described above, the active compundsuseul i th 5Usaind-release formulations Of the present 00 5 invention, include the sulfonamide, sulfamate, and carbamate compounds of 00 isovaleric acid that, by virtue of their structural similarity to isovaleranmide, share similar pharmacological activities. Preferred sulfonami~des and N7 sulfaniates include 2 -methyl- l-propylsufonamde, 1-me thylethyl sulfamate, and 2 -methyl-1-propyl sulfamnate. Preferred carbarnates include isobuty1carbamate (C )CC2CN2 and isopropylcarbamate (CIHL)2CHOCONH2).
Preparation of active compound The compounds of the present invention may be prepared using synthetic methods that are well known in the art. For example, many of the carboxylic acid precursors of the amide compounds are commercially available Aldrich Chemical Co., Milwaukee, WI) and can be converted into the corresponding amide by preparation of the acid chlori de with thionyl chloride or oxalyl chloride, followed by reaction with ammonia or an amine. For compounds containing a hydroxyl group distal to the carboxyl group, the hydroxyl group first is protected using a suitable protecting group as described, for example, in Green, "Protective Groups in Organic Synthesis," Wiley -Press (1981), prior to preparation of the acid chloride. 2 -hydroxy and 3-hydroxy isovaleramide are metabolites of isovaleranmjde in vv, and can be isolated in high yield from the urine of a patient being treated with isovaleramide.
For compounds where the starting acid is not commercially available, the required acid can be prepared by straightfoward methods of organic synthesis known to the skiled chemist. For example, carboxylic acid esters may be deprotonated with a strong non-nucleophilic base, such as lithium diisopropylamide, followed by alkylation with methyl iodide or methyl Strifluoromethanesulfonate. The alcylated ester is hydrolyzed and converted to wthe amide by the methods described above.
SWhen the compounds contain one or more asymmetric centers, the Ni, individual enantiomers may be prepared from optically active starting 0 5 materials, or separated by traditional methods of resolution, such as fractional ci crystallization of salts with chiral amines, or by preparation of amides with N, chiral amides, chromatographic separation, and hydrolysis of the amides.
SAlternatively, the amides can be prepared by well known methods of Sasymmetric synthesis, such as alkylation of an ester or amide of the acid prepared using a chiral auxiliary. For example, see Evans et al., Tetrahedron 44:5525 (1988), and Fadel et al., Asymmetry 1994:531.
The present invention thus contemplates a variety of pharmaceutical compositions containing the active compounds described above (including isovaleramide, isovaleric acid, and/or its pharmaceutically acceptable salts, substituted amides, alcohol esters, sulfonamide, sulfamate, and carbamate analogs) as active ingredients in a sustained-release formulation that is suitable for oral, IV, parenteral, transdermal, transmucosal, intranasal, buccal, or rectal administration. Although such compounds may be present as incidental by-products in certain pharmaceutical formulations which are outside the scope of the present invention, the common feature of the present formulations is that isovaleramide, isovaleric acid, and/or its pharmaceutically acceptable salts, substituted amides, alcohol esters, and sulfonate, sulfamate, and carbamate analogs, are present in a standardized amount. That is, the pharmaceutical formulations contain a predetermined, chemically-defined, and quantifiable amount of at least one of such compounds to enable the determination of the quantity of a particular composition required to achieve the dosage levels described herein.
Sustained-reIeae compositions The present invention provides sustained-release pharmaceutical compositions comprisig the activecopu dsrbdaveTh phrmcetia compostin can contain a single active compound or a 005 combination of two or more of the active compounds. Also, isovaleraxnide and/or related compounds can be used in combination with other pharmaceutically active ingredients.
A"unit" of drug herein refers to an individual item containingdrg such as a capsule or tablet. "Unit dose" denotes the amount of drug contained in a unit of the drug. The term "dose or "dosage" refers to the amount of drug administered at a single point in time. For example, oral administration of two units tablets) at a single Point in time, each having a unit dose of 100 mg of drug, resul. ts in a drug dose of 200 mg. "Daily dose" means the amount of drug administered over a one day 2 4-hour) period.
The sustained-release composition of the present invention can comprise any unit dose of active compound, generally between about 100 to 1200 mg.
Preferable unit doses of 300 mg and 600 mg can be administered in a variety of combinations to obtain doses of 300, 600, 900, 1200 and 1500, 1800, 2100, and 2400 mg. Smaller unit doses can be produced for pediatric administration, generally from about 50 to 300 mg in amount. A daily dose of drug could range between about 100 to 4800 mg, but more typically, would range between about 300 to. 2400 mg.
The approach to determine drug treatment parameters, such as the total daily dosage, unit dose and schedule of administration, is well known and depends on a number of factors, including, for example, mode of administration, safety, tolerability, effectiveness, bioavailability and Pharmacokinetic properties Of the composition. Drug compositions with sustained-release properties can'initially be screened for resistance to dissolution in an in vitro simulated gastric and intestinal environment (Example Promising sustained-release Compositions are then tested in vivo for safety, tolerability, effectiveness, bioavailability and pharmacokinetic properties ;Z (Examples I and 3).
Nq Sustained-release formulations are designed to achieve a stable serum concentration of the drug over a convenient period of time 12 hours) 00 5 even though the drug has a short half-life. A stable drug level is achieved by releasing drug into the system at a sustained rate that approximates its rate of clearance. The amount of drug in each dose of the formulation depends on several factors including, for example, the effective therapeutic serum concentration of the drug as well as the bioavailability and pharmacolinetic properties of the drug in the sustained-release formulation. For example, the amount of isovaleramide active compound represents about 40-70% by weight of a sustained-release tablet, with the remainder of the composition providing sustained-release characteristics and/or assisting in formulation. Methods for determining and evaluating these characteristics are well known in the art.
An extensive variety of sustained-release compositions and devices have been described for sustained and controlled release of pharmaceutical compositions. For example, see Baker, CONTROLLED RELEASE
OF
BIOLOGIC
A
LLY ACTIVE AGENTS 73 (Wiley-Interscience, 1987); Heler, "Biodegradable Polymers in Controlled Drug Delivery," in 1 CRC
CRITICAL
REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS 39-90 (1987); Di Colo, "Controlled Drug Release From Implantable Matrices Based On Hydrophobic Polymers," Biomaterials 13: 850-56 (1992); CoNTRoLLED
RELEASE
TECHNOLOGIES: METHODS, THEORY, AND APPLICATIONS, Agis F. Kydonieus, ed. (CRC Press Inc., 1985). Many of the previously described approaches for sustained-release formulations can be adapted for sustained release of the active compounds described herein. One skilled in the art can manipulate the individual formulations to achieve a desired release rate of drug release in both in vitro and in vivo testing formats following the principles of sustained drug delivery discussed above. In addition, a variety of pharmaceutically acceptable carrier materials are known in the art (see, "Remington's Pharmaceutical -11- Sciences," 18th ed., Gennaro, ed., Mack Publishing Company, Easton, Pa., 19;and "The Pharmacological Basis of Therapeutics, "Goodman and Gilmran, eds., 8th Edition, Pergamon Press, 1990) and these can be included in sustained release formulations of the present invention.
005 The sustained-release composition of the present invention can be N provided in solid unit form. It may be formed into any desired solid drug unit, N ~including, for example, capsules, tablets, multiparticulate compositions, caplets, gelcaps, lozenges, suppositories, pessaries or implants.
The inventive compositions can be administered orally using solid oral drug units such as, tablets, caplets, gelcaps, capsules, granules, multiparticulate compositions, or using a liquid-based drug unit. These compoundis also can be added to foods and beverages for oral administration, particularly in the case of drug granules which can be sprinkcled on food. In addition, the sustainedrelease compositions can be formulated in chewable form chewing gum) to facilitate oral delivery and absorption, particularly in pediatric applications.
The inventive compositions also can be administered by injection or other systemic routes, such as transdermal or transmucosal administration, for example, nasally, buccally, or rectally, via suppositories. Oral administr~ation is more convenient and, hence, is preferred.
Following oral administration, the sustained-relae composition slowly releases the pharmacologically active ingredient within the body as the formulation progresses along the gastro-intestija tract. In this regard, the gastro-ntestina tract is considered to be the abdominial portion of the alimentary canal, i.e. the lower end of the esophagus, the stomach and the intestines.
A typical sustained-release formulation of the present invention comprises the active compound and a matrix, where the matrix comprises a gelling agent that swells upon contact with aqueous fluid. The drug entrapped within the gel is released from the formulation slowly, upon dissolution of the gel, and then is available for uptake into the body at a sustained rate. The -12- Sactive compound can be evenly dispersed within the matrix or can be present Sas pockets of drug in the matrix. For example, the drug can be formulated into N small granules which are dispersed within the matrix. In addition, the granules of drug also can include a matrix, providing a primary and a secondary matrix, 00 5 as described in U.S. Patent No. 4,880,830.
The gelling agent and film forming/gelling polymers are preferably a 0 polymeric material, which can include, for example, any pharmaceutically acceptable water soluble or water insoluble slow releasing polymer such as Sxanthan gum, gelatin, cellulose ethers, gum Arabic, locust bean gum, guar gum, carboxyvinyl polymer, agar, acacia gum, tragacanth, veegum, sodium alginate or alginic acid, polyvinylpyrrolidone, polyvinyl alcohol, methyl cellulose carboxymethyl cellulose (CMC), hydroxypropyl methylcellulose, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), ethylcellulose acrylic resins or mixtures of the above U.S. Patent No. 5,415,871).
A
particularly preferred polymer is xanthan gum.
The gelling agent of the matrix also can be a heterodisperse gum comprising a heteropolysaccharide component and a homopolysaccharide component which produces a fast-forming and rigid gel, as described, for example, in U.S. Patent No. 5,399,359. The matrix also can include a crosslinking agent such as a monovalent or multivalent metal cations to add rigidity and decrease dissolution of the matrix, further slowing release of drug The amount of cross-linking agent to be added can be determined using methods routine to the ordinary skilled artisan.
The choice of gelling agent depends upon the active compound and the overall configuration of the sustained-release composition, although use within a range of 10 to 70 parts per 100 parts by weight of the active compound is generally preferred. In the case of an oral sustained release formulation, the amount of xanthan gum generally between 5 to 20% of the weight of the -13gcomposition is preferred, an amount between 5 to 10% is more preferred and an amount of about 6 is most preferred.
Although in some situations, the active compound and matrix can together represent virtually a complete sustained-release formulation, in 00 0 5 general, additional components that are necessary to further retard release of Sactive compound or to assist in formulation excipients) will be required.
For example, in tablets and multiparticulate composition formulations §containing 400 mg isovaleramide, the amount of gelling agent and drug is preferably about 30 to 70% of the formulation, more preferably about 40-60% of the formulation and most preferably about 50% of the formulation In tablets with unit drug doses of 600 mg, the amount of gelling agent and drug is preferably about 50-90% of the formulation, more preferably about 65-75% of the formulation and, most preferably, about 72% of the formulation.
In multiparticulate composition formulations with unit drug doses of 600 mg, the amount of gelling agent and drug is preferably about 40-85 of the formulation, more preferably about 50-70% of the formulation and, most preferably, about 60% of the formulation.
The matrix of the sustained-release composition also can include one or more pharmaceutically acceptable excipients recognized by those skilled in the art, i.e. formulation excipients. Such excipients include, for example, binders: polyvinylpyrrolidone, gelatin, starch paste, microcrystalline cellulose (such as AVICEL PH 101®, available from FMC Pharmaceutical Division, Philadelphia, PA); diluents (or fillers): starch, pregelatinized cornstarch (such as STARCH 1500®, available from Colorcon, West Point, sucrose, dextrose, lactose, fructose, xylitol, sorbitol, sodium chloride, dextrins, calcium phosphate, calcium sulphate; and lubricants: stearic acid, magnesium stearate, calcium stearate, Precirol (mixture of mono-, di- and triesters of palmitic and stearic acid with glycerol) and flow aids for example talc or colloidal silicon dioxide. Pregelatinized cornstarch, microcrystalline cellulose, and a mixture of lactose and magnesium stearate are preferred as a formulation excipient.
-14- If necessary, such formulation excipients can be present in large ;Z quantities, particularly where the composition comprises a small amount of Npharmacologically active ingredient. The relative amounts of excipient to drug and gelling agent (and/or other matrix components) or excipient to gelling agent depend on a number of factors. In general, with a unit drug dose of about 400 mg, the amount of excipient relative to gelling agent (and/or other matrix components) and drug in tablet formulations is preferably 30 to 60% by weight of the composition, more preferably about 30 to 50% by weight of the composition, and most preferably about 39%, by weight of the composition.
With unit drug doses of 600 mg, the amount of excipient relative to gelling agent (and/or other matrix components) and drug is preferably about 10 to by weight of the composition, more preferably about 15 to 20% by weight of the composition, and most preferably about 16% by weight of the composition. Thus, a preferred range of excipient is about 16-39% by weight of the composition.
The matrix of the sustained-release composition of the present invention can further include a hydrophobic material which slows hydration of the gelling agent without disrupting the hydrophilic nature of the matrix, as described in U.S. Patent No. 5,399,359. In certain preferred embodiments of the present invention, the hydrophobic material is included in the matrix in an amount from about 1 to about 20 percent by weight and replaces a corresponding amount of the formulation excipient. A solvent for the hydrophobic material may be an aqueous or organic solvent, or mixtures thereof.
The hydrophobic polymer can include, for example, a hydrophobic cellulosic material such as alkylcellulose or ethylcellulose, polymers or copolymers derived from acrylic or methacrylic acid esters, zein, waxes, shellac, hydrogenated vegetable oils, waxes and waxy substances such as carnauba wax, spermaceti wax, candellila wax, cocoa butter, cetosteryl alcohol, beeswax, ceresin, paraffin, myristyl alcohol, stearyl alcohol, cetylalcohol and stearic acid. Other Pharmaceutically acceptable hydrophobic materials are known to those skilled in the art.
Examples of commercially available alkylcelluloses are AQUACOAT® (aqueous dispersion of ethylcellulose available from FMC Pharmaceutical 00 5 Division, Philadelphia, PA) and SURELEASE® (aqueous dispersion of ethylcellulose available from Colorcon, West Point, PA). Examples of commercially available acrylic polymers suitable for use as the hydrophobic material include EUDRAGIT® RS and RL (copolymers of acrylic and methacrylic acid esters having a low content 1:20 or 1:40) of quaternary ammonium compounds) (R6hnm America Inc., Piscataway,
NJ).
The sustained-release composition of the present invention also can include a film-coating that surrounds the active compound or a combination of the active with matrix to retard access of liquids to the active compound and/or retard release of the active compound through the film-coating. The filmcoating can provide characteristics of gastroresistance and enterosolubility by resisting rapid dissolution of the composition in the digestive tract. Such filmcoating can comprise gels, waxes, fats, emulsifiers, combination of fats and emulsifiers, polymers, starch, and the like.
Film-coatings for sustain release compositions preferably comprises a polymeric coating material such as a hydrophobic polymer, e.g., ethylceUulose, which is applied together with a plasticizer. The rate of drug release is effected by adjusting the amount of film-coating applied, the plasticizer type, the amount of plasticizer added, and by including release modifying agents such as aqueous polymers to the coating formulation.
In a tablet composition of the present invention, the film-coating generally represents about 5-15 by weight of the sustained-release composition. Preferably, the core by weight represents about between 88-91% (or about 90%) of the composition with the remaining 9% to 12% (or about provided by the coating.
-16- In a multiparticulate composition formulation of the present invention, Sthe film-coating generally represents about 1-10% by weight of the sustainedrelease composition. Preferably, the core by weight represents about between 92-96% of the composition with the remaining 4% to 8% (or about 6%) 00 5 provided by the coating.
SCoating can be applied from a solution, suspension or as dry powder.
O A solution formulation can be in organic solvent or aqueous solvent. Aqueous solvent systems are preferred for general safety reasons. The active compound Scan be coated, either alone or combined with a matrix. The coating preferably is applied to the drug or drug and matrix combination as a solid core of material as is well known in the art.
Polymers useful for coating compositions of the present invention include a cellulosic derivative, for example, methylcellulose
(METHOCEL®
A: Dow Chemical Co., Midland, Michigan), HPMC with a molecular weight between 1,000 and 4,000,000 (METHOCEL® E: Dow Chemical; or PHARMACOAT®: Shin-Etsu Chemical Co., Tokyo, Japan), hydroxypropyl cellulose with a molecular weight between 2,000 and 2,000,000, ethyl cellulose, cellulose acetate, cellulose triacetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate trimellitate (Eastman Kodak), carboxymethylethyl cellulose (DUODCEL®: Lehmann Voss, Hamburg, Germany), HPMC phthalate, ethylcellulose, methylcellulose. Other polymers useful in a coating composition include acrylic polymers such as polymethacrylic acid-methacrylic acid copolymer (Type A 1:1 EUDRAGIT® L100; Rohm Pharma Gmbh, Weiterstadt, Germany; Type B 1:2 EUDRAGIT® S100; and Type C 1:1 EUDRAGIT® L100-55, aqueous dispersion solids, EUDRAGIT® L30D), poly(meth)acryl ester: poly(ethyl acrylate, methyl methacrylate EUDRAGIT® NE30D aqueous dispersion solids, polyaminomethacrylate EUDRAGIT® E100, poly(trimethylammonioethyl methacrylate chloride)ammoniomethacrylate copolymer, EUDRAGIT® RL30D and EUDRAGIT® RS30D, as well as -17carboxyvinyl polymers, polyvinylalcohols, glucans scleroglucans, mannans, Sand xanthans.
SAqueous polymeric dispersions useful for coating the present invention include EUDRAGIT® L30D and RS/RL30D, and NE30D,
SURELEASE®
(Colorcon, Orpington Kent, United Kingdom) brand ethyl cellulose, EC brand N-10F ethyl cellulose, AQUATERIC® (FMC, Philadelphia, PA) brand cellulose acetate phthalate, COATERIC® (Colorcon Inc., West Point,
PA)
brand Poly(vinyl acetate phthalate), and AQUACOAT®-brand hydroxypropyl C methylcellulose acetate succinate. Most of these dispersions are latex, pseudolatex powder, or micronized powder mediums.
A plasticizing agent preferably is included in the coating to improve the elasticity and the stability of the polymer film and to prevent changes in the polymer permeability over prolonged storage. Suitable conventional plasticizing agents include, for example, diethyl phthalate, glycerol triacetate, acetylated monoglycerides, acetyltributylcitrate, acetyltriethyl citrate, castor oil, citric acid esters, dibutyl phthalate, dibutyl sebacate, diethyloxalate, diethyl malate, diethylfumarate, diethylphthalate, diethylsuccinate, diethylmalonate, diethyltartrate, dimethylphthalate, glycerin, glycerol, glyceryl triacetate, glyceryltributyrate, mineral oil and lanolin alcohols, petrolatum and lanolin alcohols, phthalic acid esters, polyethylene glycols, propylene glycol, rape oil, sesame oil, triacetin, tributyl citrate, triethyl citrate, and triethyl acetyl citrate, or a mixture of any two or more of the foregoing. Plasticizers which can be used for aqueous coatings include, for example, propylene glycol, polyethylene glycol (PEG 400), triacetin, polysorbate 80, triethyl citrate, diethyl d-tartrate.
A coating solution comprising a mixture of HPMC and aqueous ethylcellulose AQUACOAT® brand) as the polymer and dibutyl sebacate as plasticizer is preferred for coating the tablet compositions of the present invention (AQUACOAT® ECD is an aqueous dispersion of ethylcellulose polymer comprising total solids ethylcellulose (24.5- 29.5%) sodium lauryl sulfate cetyl alcohol hydrogen -18peroxide (<50 ppm), heavy metals (<10 ppm), total aerobic microbial count S(<100 cfu/g), total yeast and mold count (<20 cful/g) with a pH of 4.0-7.0 and a viscosity of 150 cps). Preferably, the plasticizer represents about 1-2% of the composition.
In addition to the polymers, the coating layer can include an excipient 1to assist in formulation of the coating solution. Such excipients may include a O lubricant or a wetting agent. Suitable lubricants as excipients for the film Scoating include, for example, talc, calcium stearate, colloidal silicon dioxide, Oglycerin, magnesium stearate, mineral oil, polyethylene glycol, and zinc stearate, aluminum stearate or a mixture of any two or more of the foregoing.
Suitable wetting agents include, for example, sodium lauryl sulfate, acacia, benzalkonium chloride, cetomacrogol emulsifying wax, cetostearyl alcohol, cetyl alcohol, cholesterol, diethanolamine, docusate sodium, sodium stearate emulsifying wax, glyceryl monostearate, hydroxypropyl cellulose, lanolin alcohols, lecithin, mineral oil, onoethanolamine, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, propylene glycol alginate, sorbitan esters, stearyl alcohol and triethanolamine, or a mixture of any two or more of the foregoing.
In another aspect of the present invention, the sustained-release composition of the present invention comprises a semi-permeable wall surrounding the active compound, the semi-permeable wall being permeable to the passage of fluid but impermeable to the passage of said active compound.
The composition includes one or more exits through the semi-permeable wall for sustained release of the active compound, in accordance with the method of disclosed in U.S. Patent No. 5,674,895. In such cases, the active compound can be placed inside the semi-permeable wall alone or as a sustained-release formulation such as with a matrix and/or film-coating.
In another embodiment, an intact film coat with pores for releasing drug through osmotic action can be produced as described in U.S. Patent -19- No. 5,256,440. According to this approach, a sustained-release drug core is ;Z coated with a film that comprises a detachable zone and a fixed zone, wherein the detachable zone, when exposed to an environment of use, detaches from the device to expose a portion of the surface of the compressed core beneath 005 the detachable zone of the film coating, and the fixed zone remains attached to the compressed, core. The pores are produced by inscribing intagliation) one or more areas on the surface of a drug core prior to coating. An aqueous dispersion of a polymeric coating, latex, is then applied to the intagliated dosage form core. When placed in an aqueous environment of use, the film coating within the circumscribed region of the dosage form surface is reproducibly detached, leaving a coated core tablet with a predefined discrete portion of the core surface exposed to the environment of use.
In another approach, an intact film coat with pores can be formulated by preparing a film coating where -an insoluble polymer such as cellulose acetate is mixed with a soluble material such urea or sucrose. Appel et al., Phann. Res., 8:600 (1991). After coating, the soluble material becomes detached from the film coat, leaving small1 pores for releasing drug. Rates of release varying from 1 to 100% can be achieved by varying the coating thickness, pore-former level, and plasticizer type and concentration The compression tablet described above also can include multiple ,layers, each compressed in succession a multiple-compression tablet), each layer having a discrete zone, one for rapid release and one for delayed release, both of which combine to produce sustained release. See U.S.
Patent No. 4,996,061. Such tablets include a fu~lly encased tablet with the outer material completely surrounding the inner material, a layered tablet, which is nude up of two or more distinct layers or discrete zones of granulation compressed together with the individual layers lying one on top of another, and the inlay tablet, also referred to as a dot, or bull's-eye tablet, where one surface of the zone corresponding to an inner core zone is exposed To obtain the gastroresistance, cellulose, acetophthalate, cellulose ;Z ~acetopropionate, cellulose trimelitate, acrylic and methacrylic polymers and copolymers with different molecular weight and solubility dependent on different pH values may be applied as a polymer coating. See U.S. Patent 005 No. 5,399,359. The materials may be applied on the finished pharmaceutical form (core +external layer) by the classic film-coating process using solutions in organic solvents or aqueous dispersions and operating by nebulization in basin or in fluidized bed. The gastroresistant and enterosoluble materials may also be used in association with retarding polymers.
A compressed core containing the active compound and a film-coating around the core also can comprise a sugar coating containing a further dose of active drug around the seal coated core as described in U.S. Patent No.
4,428,858. Sustained-release compositions of the present invention also can comprise multiple compartments as described for capsules in U.S. Patent No. 5,672,359. In a three compartment design, the outer compartment may incorporate the active compound or an odoriferous agent and excipients into a layer which coats and thus surrounds the intermediate component of the capsule. This outer component represents the rapid or instantaneous release portion of the delivery system. The intermediate compartment comprises a powder formulation which represents the intermediate rate of release portion of the delivery system. The innermost compartment incorporates the active compound in a slow release formulation as described above or as rnultiparticulate form, such as small pellets which may be coated or uncoated.
Methods of preparation A sustained-release composition according to the invention may be formed into a solid dosage presentation according to convenioa processes.
The pharmacologically active compound and matrix, together with other optional pharmaceutically acceptable excipients, are mixed and then compressed to produce a solid formulation (Example In one such method -21the Pharmacologically active compound is mixed with a minor proportion of ;Z the matrix material of the present invention to form a dry mixture Of powders.
N The mixture is then granulated using a binder material in a solvent such as an N alcoholic sol vent e.g. isopropyl alcohol or a mixture of a miscible organic 00 5 solvent and an aqueous solvent. The wet granular mass is then dried. Other N ingredients can then be added to the granules and compressed into tablets.
Alternatively, if the nature of the active compound permits, all the ingredients N may be dry mixed, including excipients, to form a homogeneous blend which is then compressed to give a tablet of the correct weight.
The solid formulations according to the invention should be compressed to a sufficient hardness to prevent the premature ingress of the aqueous medium into the core and prevention of surface pitting and breakage during coating of the core. When the final product to be manufactured is tablets, the complete mixture, in an amount sufficient to make a uniform batch of tablets, is subjected to tableting in a conventional production scale tableting machine at an appropriate pressure. Typical compression forces are about 1,000 to about 8,000 pounds.
The application of specialized coatings can be by known methods such as film coating in conventional pans or film coating in a fluidized bed suspension coating apparatus. The conventional pan coating process involves application of the coating as a film using the coating material in a solution or suspension, which is applied to the incipient beads while they are in constant motion. Heat is generally applied to dry the coating.
The fluidized bed coating process involves the application of the coating material in a solution or suspension using a spray nozzle to atomize the coating solution or suspension for application to the incipient beads, which are in motion in the fluidized bed apparatus. Generally, in beads that are to be coated, the incipient beads move -up a column where the coating is applied and are dried in an expansion chamber. If tablets are to be coated, the process is the same, except that no colun is used. This Process is cyclic in nature, -22occurring repeatedly until the desired amount of coating is applied. For example, see REMINGTON'S PHARMACEIYrCAL SCIENCES, supra, and THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY, Lackman, Liberman and King, eds. (Lea and Febiger, Philadelphia, 1970).
00 Active Compound Dosage The sustained-release compositions of the present invention are administered in a "therapeutically effective amount" if the amount administered produces a physiologically significant effect. A physiologically significant effect results in a detectable change in the physiology of a recipient patient. In the present context, for example, a physiologically significant effect for an antispasticity agent results in the alleviation of one or more symptoms of spasticity, while the effect of an anticonvulsant agent is physiologically significant if the presence of the agent results in the reduction of the severity, number, or duration of convulsions. Similarly, for each of the pathologies recited above, the effect of a compound is physiologically significant if, upon administration to a patient, it can alleviate or reduce a clinically recognized symptom of that pathology.
The indicated dosage of isovaleramide and related compounds in treating CNS-effected disorders such as epilepsy or spasticity is on the order of to 2400 mg per dose or 1-40 mg/kg body weight. The precise dose depends several factors including the nature and dose of the active compound, the particular sustained-release formulation, and the potential for inter-subject variability.
For use as an anti-convulsant, an effective concentration of isovaleramide in the serum is expected to be about 5 to 15 }xg/ml with a target concentration of about 10 gg/ml. Thus, for a 70 kg patient with a plasma clearance of about 150 ml/h for isovaleramide (NPS 1776), a 1200 mg dose of isovaleramide administered twice daily (2400 mg daily dose) should achieve the target therapeutic steady state plasma concentration of about 10 lgg/ml.
-23- The sustained-release formulations of the present invention provide a steady ;Z rate of drug release for at least about 8 hours and more preferably for at least about 12 hours. However, drug release rates exceeding 12 hours also are contemplated In addition to use in humans, isovaleramide and related compounds can be used to treat disorders of the CNS convulsions, spasticity or anxiety) in animals such as cats, dogs, birds, horses, cattle, mink, poultry and fish. In such cases the active compound may be administered by injection or other systemic routes, such as transdermal or transmucosal administration (for example, rectal administration via suppositories), or orally, including by addition to food or drink. The indicated oral dosage of isovaleramide and/or related compounds per kilogram of body weight for convulsions or spasticity in non-human animals is about 50-1200 mg/kg, depending upon the species of animal and the route of administration.
3. EXEMPLARY PATHOLOGIES AMELIORATED BY A MODULATION OF CNS ACTIVITY A description of various CNS-related conditions and their treatment by active compounds used in sustained-release formulations of the present invention including, for example, epilepsy, spasticity, convulsive disorders, affective mood disorders, neuropathic pain syndromes, headaches, restlessness syndrome, movement disorders, have been described in WO 9 8 /08498A1 and U.S. application serial no. 09/258,882. CNS-related conditions and treatment by the above active compounds also has been described previously for anxiety, sedation and hypnotic activity in U.S. Patent No. 5,506,268. Additional conditions for application of the sustained-release compositions of the invention include cerebral insult and neuroprotection and substance abuse/craving states as described below.
CEREBRAL INSULT AND NEUROPROTECTION: Excitatory neurotrammitters such as glutamate and aspartate, as well as a variety of voltage-gated ion channels, are thought to play a central role in mediating cell -24death after a variety of cerebral insults including, but not limited to, ischemia, ;trauma, seizure and hypoglycemia. Many studies have shown that compounds or therapeutic strategies that decrease excitatory neurotransmission, for example, glutamate antagonists, ion channel blockers, and the like, elicit a neuroprotective effect in animal models of cerebral insults.
Sc Recent studies have shown that compounds such as GABAergic agents (chlormethiazole, valproate or muscimol) that enhance inhibitory Sneurotransmission, also can elicit a neuroprotective effect following the same type of cerebral insults described above (Lyden, in "Neuroprotective Agents and Cerebral Ischaemia," IRN 40, Academic Press Limited, Chapter (1997)). GABA and glycine are the primary inhibitory neurotransmitters in the mammalian central nervous system and, therefore, it is expected that enhancement of inhibitory neurotransmission via GABA or glycine agonists as well as via other agents that have been shown to increase GABA or glycine inhibitory neurotransmission (GABA/glycine re-uptake inhibitors, GABA/glycine metabolic inhibitors, GABA/glycine synthesis enhancers, GABA/glycine receptor modulators, etc.) also will produce a neuroprotective effect. Studies have shown that the combination of the GABA agonist muscimol and the glutamate antagonist, MK-801 appeared to confer an added neuroprotective effect over either agent alone, although the effect was modest (Lyden, supra, (1997)).
Kindling has been proposed as a model to search for drugs with antiepileptogenic efficacy (Wada, Epilepsia, 19: 217-227, (1974); Sato et al, Epilepsy Res., 5: 117-124, (1990)); Silver et al., Ann. Neurol., 29: 356-363, (1991)). The term "antiepileptogenic" refers to the idea of inhibiting the processes that underly the development of epilepsy. "Anticonvulsant", on the other hand, refers to the actual inhibition of seizures in an epileptic model.
Various anticonvulsants that have been shown to delay the acquisition of seizures in animal models of kindling have been proposed to be antiepileptic versus anticonvulsant the compounds are neuroprotective and block the development of seizures rather than merely blocking the seizure once the Sdisorder is in place (White et al., "Experimental Selection, Quantification, and SEvaluation of Antiepileptic Drugs (99-110) in Antiepileptic Drugs, Fourth Edition, R.H. Levy, R.H. Matson, and B.S. Meldrum, eds., Raven Press Ltd., oO 5 Chapter 7, (1995)). Seizure kindling models are characterized by giving a subseizure eliciting electrical or chemical stimulus sub-threshold) over a Speriod of time (Goddard et al., Exp. Neurol., 25: 295-330, (1969)). The Smajority of initially non-convulsive animals that are exposed to such stimuli Sover a number of days, eventually exhibit seizure activity to these stimuli, have a permanently lowered threshold, exhibit altered manifestations of normal behavior and, therefore, are considered "kindled." The kindling phenomenon has been proposed to underlie the development of disorders such as certain types of epilepsy syndromes. Several kindling models of seizure development have been characterized.
Compounds that have been shown to delay or block acquisitions of seizures in these kindling models have been suggested to be a possible effective therapy following cerebral insults including, but not limited to, ischemia, haemorrhagic stoke, trauma, infection, seizure and hypoglycemia that can lead to an elevated incidence of seizure disorders ("The Epilepsies: Etiologies and Prevention," Kotagal and Luders, Eds., (1999)).
SUBSTANCE ABUSE/CRAVING: Anticonvulsants such as carbamazepine, that have shown efficacy in kindled models of epilepsy, have also demonstrated efficacy in reducing the symptoms of affective mood disorders and substance abuse/craving in patients (Post, et al., Ann. N. Y. Acad.
Sci., 537:292-308, (1988); Post, et al., Epilepsia, 25: 234-239, (1984); Post, et al., Psychopharmacol., 72: 189-196, (1981); Halikas et al., Lancet, 8638:623-624 (1989); Blumer et al., Compr. Psychiatry, 29(2):108-22 (1988)).
Post et al., Biol. Psychiatry, 11(4):403-419 (1976) have demonstrated a pharmacologic (chemical) kindling model employing subconvulsive doses of cocaine as the stimulus. The progressive human response to high cocaine -26usage such as irritability, restlessness, hypervigi ance, and paranoia may be a ;Z human equivalent of the kindling phenomenon observed in animals.
Several kindling models of seizure development have been N characterized. Seizure kindling models are characterized by administr~ation of a 00 .5 sub-seizure eliciting electrical or chemical stimulus sub-threshold) over a period of time (Goddard et al., supra, (1969)). The majority of initially non- N convulsive animals that are exposed to such stimuli over a number of days N- eventually exhibit seizure activity to these stimuli, have a permanently lowered threshold, exhibit altered manifestations of normal behavior and therefore are considered "kindled." A kindling phenomenon has been proposed to underlie the development of disorders such as certain types of epilepsy syndromes, substance abuse/craving and affective mood disorders such as bipolar (Post et al. supra, (1981, 1984, and 1988); and Ballenger, et al., Br. J. Psiychiatiy, 133:1-14, (1978).
The pharmaceutical compositions of the invention display anticonvulsant activity and efficacy in animal models of kindling and, accordingly, the inventive pharmaceutical compositions should be useful in treating conditions associated with substance abuse/craving.
4. DEMONSTRATING THERAPY..IMPLICATIG
ACTIVITY
The suitability and effectiveness of a given sustained-release pharmaceutical formulation for the alleviation of a pathology, as discussed above, can be demonstrated using animal models such as (but not limited to) those described below.
The Mutant Spastic Mouse The mutant spastic mouse is a homozygous mouse that carries an autosomal recessive trait of genetic spasticity due to a deficit of glycine receptors throughout the central-nervous system. This application of this animal model to spasticity drug testing has been described previously in WO 98/08498AI.
-27- The Acute/Chronic Spinally Transected Rat And The Acute Decerebrate Rat There are several models of spasticity including the acute decerebrate rat, the acute or chronic spinally transected rat, and the chronically spinal cordlesioned rat. Wright, et al., Clin. Orthop., 253:12 (1990). These models 00 have also provided methods to test various treatment paradigms that have led to similar treatments being tested in humans and are described in greater detail in WO 98/08498A1.
Primary Observation Irwin Test In The Rat N 10 This method is based on that described by Irwin, Psychopharmacologia 13: 222-57 (1968). It is used to detect physiological, behavioral, and toxic effects of a test substance, and indicates a range of dosages that can be used for later experiments. This method is described in greater detail in WO 98/08498A1.
Rotarod Test In The Rat and Mouse This is a test of neurological deficits using the method described by Dunham et al., J. Am. Pharm. Assoc., 46: 208-209 (1957), involving placement of rats or mice on rotating rod. This model is described in greater detail in WO 98/08498A1.
Anticonvulsant Activity There are numerous in vivo models involving different kinds of seizures and behavioral effects that are relevant for clinically distinct forms of epilepsy.
These include for example, the Frings audiogenic seizure-susceptible mouse for reflex epilepsy, which has been described in greater detail in WO 98/08498A1.
Anti-Manic Activity The amphetamine-induced hyperactivity model in rats can be used to assess the possible use of compounds in the treatment of affective mood disorders. In addition to being a test for classical and atypical antipsychotic activity, this procedure has also been proposed as a simple animal model of manic behavior. Costall er aL, Brain Res., 123: 89-111 (1977).
-28- Neurogenic Inflammation Of The Meninges Neurogenic inflammation within the meninges has been proposed as an event in the underlying pathology of migraine headaches. Lee et al., Brit. J.
Pharmacol., 116:1661-67 (1995). Compounds are tested for their ability to block the leakage of radiolabeled bovine serum albumin within the dura mater post trigeminal stimulation.
Analgesic Properties There are many whole-animal assays for determining analgesic properties, such as writhing, hotplate, tail flick, arthritic pain, paw pressure tests, and the Bennet or Chung models of neuropathic pain. Albe-Fessard et al., in ADVANCES IN PAIN RESEARCH AND THERAPY, Chapter 13, pages 11-27, (Raven Press, 1990).
Movement Disorders and Restlessness Syndromes Animal models exist for the study of movement disorders and restlessness syndromes, for example, drug-induced akathisias, serotonin syndrome, rotation induced by unilateral nigral lesions (Lloyd et al., Med.
Biol., 65(2-3):159-65 (1987)). Additionally, individual case reports of anecdotal efficacy of compounds in humans have been a source for support for these indications. Mellick et al., Am. J. Emerg. Med., 13(1):96 (1995); and Olson et al., Am. J. Med., 102:60-66 (1997).
Neuroprotection Kindling has been proposed as a model that can be used to identify drugs with antiepileptogenic efficacy (Wada, supra, (1974); Sato et al., suprai, (1990); and Silver et al., supra, (1991). The term "antiepileptogenic" refers to the idea of inhibiting the processes that underly the development of epilepsy thereby providing a "neuroprotective" effect. "Anticonvulsant," on the other hand, refers to the acutal inhibition of seizures in an epileptic model. Several models of kindling are useful. The amygdala-kindled rat is such a model (Tober, Eur. J. Pharmacol., 15:163-169, (1996)). Seizure kindling models are characterized by giving a sub-seizure eliciting electrical or chemical stimulus -29sub-threshold) over a period of time (Goddard et al., supra, (1969)).
The majority of initially non-convulsive animals that are exposed to such N stimuli over a number of days, eventually exhibit seizure activity to these stimuli, have a permanently lowered threshold, exhibit altered manifestations 00 5 of normal behavior and therefore are considered "kindled." Acute cerebral insults such as status epilepticus, traumatic injury and stroke induce damage to selective neuronal populations in the hippocampus (Matsuyama et al., J. Cereb. Blood Flow Metab., 13: 229-234, (1993)); and Sloviter, Science, 235: 73-76, (1987)) suggesting that substances designed to prevent the neuronal damage that occurs in a variety of human neurological diseases would be therapeutically useful. In Jolkkonen et al., Neuroreport, 7: 2031-2035, (1996) it was found that augmentation of GABAergic inhibition by chronic infusion of the GABA transaminase inhibitor, vigabatrin, prevented the delayed seizure-induced damage following kainate-induced status epilepticus.
Stroke in humans is a highly variable clinical condition, dependent upon pre-existing disease in a patient, the site and severity of the stroke, the type of stroke (ischemic or hemorrhagic), and the time from onset to presentation for treatment. A number of animal models of stroke have been developed over the past several years to aid in our understanding of the pathophysiological mechanisms of neuronal injury and to allow for the evaluation of potential neuroprotective agents (Ginsberg et al., Stroke, 20: 1627-1642 (1989); and Hunter et al., Trends. Pharmacol. Sci. 16:123-128 (1996)). A major goal of these animal models has been to reduce the biological variability, by controlling or eliminating the variables mentioned above, to facilitate data analysis and interpretation. In doing so, however, these animal models do not perfectly mimic the human condition.
Substance Abuse/Craving Kindling phenomenon has been proposed to underlie the development of disorders such as epilepsy substance abuse/craving and affective mood disorders such as bipolar (Post et al. 1981: Post et al., 1984; Ballenger et al., 1978; Post et al., 1988). Anticonvulsants, such as cambamazepine, that have Sshown efficacy in kindled models of epilepsy, have also demonstrated efficacy Sin reducing the symptoms of affective mood disorders and substance abuse/craving in patients (Post and Weiss, supra (1989), Halikas et al., supra, (1989); and Blumer et al., supra, (1988)). Post et al., Biol. Psychiay 11: 403- S419, (1976)) have demonstrated a pharmacologic (chemical) kindling model employing subconvulsive doses of cocaine as the stimulus. The progressive human response to high cocaine usage such as irritability, restlessness Shypervigilance, and paranoia may be a human equivalent of the kindling phenomenon observed in animals. Recently, the anticonvulsant drug, vigabatrin, was proposed as a possible treatment for cocaine or nicotine craving (Dewey, et al., Synapse, 31:76, (1999)).
The therapeutic effects of isovaleramide, isovaleric acid, and related compounds, as illustrated in various of the assays described above are exploited to unexpected advantage in sustained-release formulations of the present invention. These formulation can be used to treat the pathologies described above, including, for example, spasticity, bipolar affective disorder and convulsions/seizures. With this background, the present invention will be understood more readily by reference to the following examples, which are provided for purposes of illustration and are not intended to be limiting of the invention.
2t Example 1 Pharmacokinetic Properties of Isovaleramide Orallv Administered in Hu ns Isovaleramide (NPS1776) was orally administered in a double-blind, placebo-controlled, ascending single dose study conducted in two groups of healthy young male Caucasian subjects and one group of healthy young female Caucasian subjects to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of the drug. Various amounts of the drug were dissolved -31in 250 mL of a flavored soft drink (powdered soft drink diluted in mineral ;Z water) and administered as an oral solution.
Safety and tolerability: Isovaleramide was well tolerated following oral administration of 100 to 005 1600 mg to haealthy male subjects. There were few drug-related adverse events during the study, and all were mild in severity. The most common adverse events were polyuria and headache. There were no dose-related trends in the incidence or severity of adverse events, or any difference in the incidence or severity of adverse events reported. Similar results were obtained in a 1200 mg dose level female group administered the drug for gender comparison. For all dose levels, there were no clinically significant drug-or dose-related changes in vital signs (body temperature, supine and standing blood pressure and heart rate), 12-lead ECG, clinical laboratory assessments or physical examination.
Pharmacokinetics: Isovaleramide administered orally in the absence of a sustained-release formulation was rapidly absorbed and rapidly eliminated in human subjects (Table Systemic exposure to the drug increased with increasing.oral doses from 100 to 1600 mg in male subjects. The increase in and AUC was slightly greater than proportional to the increase in the dose level. Values for tr and t,4 did not markedly vary with the dose, while the plasma clearance and volume of distribution decreased with increasing dose. Pharmacokinetic parameters of NPS 1776 (1200 mg dose) in females were not markedly different to those in males with the exception of t"A, which was slightly lower in females (1.89 h) than in males (2.43 h).
Table 1: Pharmacokinetic Parameters for Oral Isovaleramide in Male Humans -32- S(mLh) 0 15 18 1 164 148 130 m (37.18.8) (29.8 (23.7) (26.8) (17.5) *Geometric mean (95% confidence intervals) S§Arithmetic mean (SD) tHarmonic mean (min-max) The results show that isovaleramide has a short half-life of about 00 5 hours in humans when orally administered in the absence of a sustained-release formulation. For all doses, the maximum drug concentration was achieved in I less than one hour and typically in about 30 minutes following administration.
For a 2.5-hour half-life, a single dose of drug results in about a change in the drug concentration in the blood over a 12-hour period. If one assumes an effective target blood concentration of the drug of about 10 pg/mL, then administration of a 1200 mg dose of the drug falls below the effective concentration at about 5 hours after administration. That is, 1200 mg results in an initial maximum blood concentration of about 27 mg which decreases four fold two half lives to about 6-7 mg at five hours after injection.
Thus, use of a sustained-release formulation could avoid having to administer, say, a 1200 mg dose every 4 to 6 hours, in order to maintain a therapeutic concentration of drug in the serum.
Example 2 Prearationof Sustained-release Pharmaceutical Formulation of Isovaleramide Example 2.1 This example describes the preparation of film coated tablets of isovaleramide (NPS 1776) which were designed to release drug in a sustained manner. The formulations were designed to deliver a specific amount of drug over a specific course of time to achieve a specific plasma drug concentration, while minimizing peak to trough differences that occur in vivo. This was achieved despite the fact that the tablet contains a very high drug load and the drug is very water soluble.
-33- SSustained release was achieved with two barriers. An outside barrier Sis an ethyl cellulose/hydroxypropyl methyl cellulose film coat that retards diffusion of water into the tablet core and acts as a barrier against drug diffusion out from the inner core of the tablet. An inside barrier comprises xanthan gum in the tablet core matrix, which hydrates and swells to form a viscous gel A. Manufacturing Procedure for dual barrier tablet C N Preparation of the tablet core 1. Active drug Isovaleramide; NPS 1776; Oread, Lawrence, Kansas; cGMP grade) was dispersed by passage through a #30 mesh screen.
2. Drug, xanthan gum XANTURAL®; Monsanto, St Louis, Missouri; grade NF) and lactose monohydrate form, spray dried,: Oread, Palo Alto, CA; NF grade) were mixed into a 1-L glass jar and blended in a Turbula mixer for four minutes at 96 rpm.
3. Magnesium stearate Oread, Palo Alto, CA; NF grade) was added and the mixture blended for one minute.
4. The final blend was compressed into caplets using 0.32-inch x 0.75inch x 0.060-inch tooling to a target weight of 800 mg and a target hardness of 8 kP, and target thickness of 0.25 inch.
Coating of the tablet cores 1. Hydroxypropyl methylcellulose (HPMC; Dow Chemical Co., Midland, Michigan; NF grade) solution was prepared by adding HMPC slowly to purified water heated to approximately 80"C. The solution was allowed to cool to room temperature by placing vessel in a cold water bath. Additional water was added to prepare the final requisite amount of HPMC solution.
-34- 2. AQUACOAT® ECD /dibutyl sebecate mixture was prepared by adding dibutyl sebacate (DBS: Morflex Inc., Greenboro, North Carolina; NF grade) to AQUACOAT® ECD FMC Pharmaceutical Division, Philadelphia, PA) while mixing. Mixing was continued for a minimum of O, 5 minutes.
3. The HPMC solution was added slowly to the AQUACOAT® ECD/DBS mixture.
4. The core tablets were loaded into a coating apparatus (Vector
LCDS
3 coater) fitted with a 1.3 liter coating pan and warmed until an outlet temperature of 401C was reached.
The tablets were spray coated until the planned theoretical weight gain (based on core tablet weight) was achieved, however, after curing, the actual coating solids applied were less than the theoretical value 8% or theoretical can be 5% and 12% coat, respectively after curing). Thus, extra spray may need to be added to account for the loss upon curing.
Conditions for coating were as follows: Inlet temperature 70 0
C
Outlet temperature 40-43 0
C
Spray rate 4 Pan speed 14 rpm Fluidizing air 30-40 scfn Atomization air pressure 26 psi 6. Spraying was stopped when the requisite amount of coating suspension was applied. The tablets' were dried for approximately 5 minutes in the coating pan. The inlet temperature was adjusted during drying to keep outlet temperature below 7. The tablets were cured in an oven at 60"C for 18 hours.
B. Composition Analysis Of Sustained-release Tablets The composition of a variety of sustained release tablets are provided in tables 7-9 below.
Table 7 Formulation Composition for a 5% Film-Coated Tablet Containing 400 Mg Isovalerainide (NIPS 1776) Lactose Monohydrate, Spray-dried 340.0 Magnesium Stereate 4.0 Core Tablet Total Weight 800.0 AQUACOAT® ECD (solids wt.) 24.4' Hydroxypropyl methylcellulose 9.8 Dibutyl sebacate 5.8 Purified water 3 (63.1) Coated Tablet Total Weight 840.0 Batch Percent wlw) 200.0 47.6 28.0 6.7 170.0 40.5 2.0 400.0 24.47 9.8 5.8 (63.1) 840.0- 95.3 2 .9 1.1 0.7
N/A
100.0 N/A Not Applicable, 'Solids content provided by 81.3 mg of suspension, 2 Solids content provided by 81.3 g of suspension, 3 Removed during processing.
Table 8 Formulation Composition for a 12% Film-Coated Tablet Containing 400 Mg Isovalerarnide (NPS 1776) IComponent ITabl etIBac 9 (Ing) Isovalerarnide (NPS 1776) 400.0 Xantbamn Gum 56.0 Lactose Monohydrate, Spray-dried 340.0 Niydroxypropyl methylcellulose 23.4 Dibutyl sebacate 14.1 Purified water 3 (151.4) Coated Tablet Total Weight 896.0 200.0 2.0 170.0 2. 0 800.0 58.52 23.4 14.1 15-1 7F .4) 896.0 Percent W/w) 4.6 6.3 7.9 ).4 89.2 2.6 1.6
N/A
Inn nvvl- 8100 Not Applicable, 'Solids content provided by 195.1 mg of suspension., 2 SoijdS content provided by 195 .1 g of suspension, 3 Removed during processing.
Table 9 Formulation HI: Composition of a 9% Film-Coated Tablet Containi ng 400 Mg Isovaleramide Component 1Tablet Batch P Prcent IsOv -amide (NPS 1776) Gum Lactose Monohydrate, Spray-dried (Ing) 400.0 56.0 340.0.
(g) 400.0 56.0 340.0 W/w 45.5 6.4 38.6 -37- N/A Not Applicable, 'Solids content provided by 162.6 mg of suspension, 3011as Content provided .by 162.6 g of suspension, 3 Remnoved during processing.
Table Formulation III: Composition of a 12% Film-Coated Tablet Containing 600 Mg Isovaleramide Component Tablet (Ing) NPS 1776 600.0 Xanthan Gum 56.0 Lactose Monohydrate, Spray-dried 140.0--- Magnesium Stearate Core Tablet Total Weight 800.0 AQUACOATO ECD (solids wt.) -48.7' liydroxypropyl methylcellulose 48.7 Dibutyl sebacate -11.7 Purified Water 2 USP (236 Coated Tablet Total Weight 909.1 m-g Percent wiw) 66.0' 6.2 15.4 0.4 5.4 5.4
NA
100.0% N/A Not Applicable, 'Solids content provided by 162.4 Ing of suspension, 2 Removed during processing., -38-
I
Example 2.2 This example describes the preparation of multiparticulate compositions of isovaleramide (NPS 1776) which were designed to release drug in a sustained manner. These formulations were designed to deliver a specific amount of 00 5 drug over a specific course of time to achieve a specific plasma drug concentration, while minimizing peak to trough differences that occur in vivo.
C. Manufacturing Procedure for Multiparticulate Compositions
(MPC)
Preparation of the tablet core 1. NPS 1776 (200-300 gm) was mixed with microcrystalline cellulose (AVICEL PH 101®) and pregelatinized cornstarch (STARCH 1500g)in a small high shear mixer. Water was added such that small agglomerates were formed.
2. The material was extruded through 1.7-mm holes with a small extruder.
The extrudate was spheronized with a maurumerizer (available from Luwa, Charlotte NC) with a plate speed of 1,000 rpm. Beads were formed within 2 minutes and were tray dried in a 50 *C oven overnight.
3. One 700-gm batch of beads (approximately 60% drug loading) was prepared and coated. Materials were screened though an #8 mesh screen to break up large lumps and added to a KG5® high shear mixer (available from Key International, Englishtown, NJ). The materials were mixed for 2 minutes with an impeller speed of 200 rpm and chopper speed of 2,000 rpm. Water was added at approximately 25 mL/minute and impeller speed was gradually increased to 350 rpm. A total of 375 mL of water was added over 20 minutes.
The energy input increased from 36 watts to 460 watts. The material was extruded and spheronized as above.
Coating of the tablet cores -39- 4. The beads were coated in a UNIGLATT® coater (available from Glatt Air Technologies, Ramsey, NJ) with a cellulose acetate butyrate solution.
Dissolution of multiparticulate compositions were performed using USP Apparatus I (rotating basket) instead of LISP Apparatus 2. Conditions for coating were as follows: Inlet air temperature Outlet air temperature Spray rate Atomization air pressure 48-52 0
C
42-44 0
C
l0g/min psi Table 11 700 gramn Batch Preparation for Multiparticulate Compositions
(MPC)
Containing 420 gram Isovaleraynide (NPS 1776) and Batch Preparation for Film Coating Solution MFC Components Isovaleerraamiddee (NPS 1776) AVICEL PFIHI 101 STARCH 1500 MPC Total Weight Coating Solution Components Cellulose Acetate Butyrate Triethyl Citrate Sucrose Acet
E
Water' Film Coat Total Weight Batch (g) 420 4- 56
W
Batch (g) 63.0 18.9 22.0 (1750 mL) (350 mL) (350 mL) 103.9 'Removed during processing.
Table 12 Film Coated Multiparticulate Composition (MIPC) Formulations Containing lsovaleramide. (NPS 1776) Component 1% Film 4% Film 6% Film 8% Coat Coat Coat Ci Wlw) wlw) Isovaleramide (NPS 59. -7 A Aq A Film oat w/w) 1776) AVICEL PH- 101 STARCH 1500 MPC Percent Total Cellulose Acetate Butyrate Triethyl Citrate Sucrose Acetone' Ethnl Water' Coated-MPC Total Wt.
Coated WPC Total 31.7 7.9 99 0.61 0.18 0.21
N/A
N/A
N/A
707.1 100.0 30.7 7.7 96 2.44 0.72 0.4
N/A
NIA
N/A
729.2 100.0 30 7.6 94 3.66 1.08 1.26
N/A
N/A.
N/A
744.7 100.0 29.4 7.4 92 4.88 1.44 1.68
N/A
N/A
N/A
760.9 100.0 Example 3 In Vitro Release and n Vivo Pharmacokinetic Analsis of Sustained-release Pharmaceutical Formulation ofis-ovaleramide Example 3. 1: Formulation Formulation II and Fomlton This example describes methods to evaluate the efficacy of sustainedrelease formulations of isovaleraride (Formulation I, Formulation 11, and Formulation IM) and related compounds. Sustained-release formulations were tested in a standard, 24-hour dissolution assay essentially as described in -41a UNrrED STATES PHARMACOPEIA (USP), edition XXIV (Apparatus 2; United States Pharmacopeia, 24, U.S. Pharmacopeial Convention, Inc., Rockville, Md., pages 1941-1947 (2000)). Dissolution of drug was determined in simulated gastric fluid (SGF) without enzymes or in simulated intestinal fluid (SIP) without enzymes as described previously pages 2235-2236). A twostage media dissolution model, involving two-hour incubation in SGF followed by 22-hour incubation in SIF (id. at 1947: entitled "Delayed-release (Enteric Coated) Article- General Drug Release Standard"), was used to project in vivo drug dissolution and to determine if a formulation has delayed release properties. The amount of drug released into SGF or SIF was determined by C18 reverse-phase high pressure liquid chtomatography.
Sustained-release Formulation I was produced as a tablet with a single barrier to retard drug release. Formulation I is the "core" tablet portion of Formulation II, shown in Table 9. Thus, Formulation I contains 400 mg of isovaleramide, xanthan gum and lactose. Oral administration of Formulation
I
to humans resulted in a peak serum drug concentration of about 4 hours, which is about four times that with isovaleramide itself (Example 1).
Sustained-release Formulation II, containing 400 mg isovaleramide, was produced as a tablet with two barriers, to retard drug release as described in Example 2.1, Table 9. In the in vitro drug dissolution assays, Formulation II showed significant delay in dissolution, with greater than 75 of the drug released into the medium after 16 hours in the two stage assay (Figure 3.1).
Pharmacokinetic analysis of Formulation I and II were performed in two groups of eight human volunteers administered orally either one sustainedrelease tablet (400 mg dose) or two tablets (800 mg dose). All 800 mg doses and 6/8 of the 400 mg doses of Formulation 11 had peak serum concentrations occurring between 8-12 hours post administration. This compares with a mean peak concentration occurring at about 3 hours for Formulation I. Formulation If was about 85 orally bioavailable, while Formulation I was about 100% bioavailable.
-42- In O
O
These results indicated that administering 1200 mg of isovaleramide twice daily (2400 mg daily dose) as Formulation II, with dosing at 12-hour C intervals, achieves a target therapeutic steady-state plasma drug concentration of 10 pg/ml. Inter-subject variability was higher than for individuals taking 0 5 Formulation I. Also, the dissolution rate of Formulation II in the in vitro assay was greater in SIF than SGF, indicating that dissolution probably is pHdependent for Formulation II. The variability observed in vivo may result from variation in gastric residence times between individuals.
Formulation III differs from Formulation I in that the former has a decreased ratio of AQUACOAT® ECD to hydroxypropyl methylcellulose in the coat. In the two-stage dissolution in vitro assay, over 80% of the drug in Formulation Im is released at 16 hours, with little apparent pH-dependency (Figure 3.1: compare SGF with SIF). These results indicate that a therapeutic steady-state plasma concentration of about 5 to 15 g/ml (target of about pg/ml) should be achieved in humans who receive two units of Formulation
III
a 1200 mg dose of isovaleramide) at about 12-hour intervals (2400 mg daily dose). The reduction in pH dependency suggests that Formulation III has improved inter-subject variability, relative to Formulation
II.
Example 3.2: Film Coated MPC Formlations 4% 6n P Formulations This example describes methods to evaluate the efficacy of the sustainedrelease, film coated multiparticulate composition formulations 6%, and 8% Film Coated MPCs) of isovaleramide and related compounds.
Sustained-release, film coated multiparticulate composition formulations were tested in a standard, 24-hour dissolution assay essentially as described in UNITED STATES PHARMACOPEIA (USP), edition XXIV(Apparatus 1; United States Pharmacopeia, 24, U.S. Pharmacopeial Convention, Inc., Rockville, Md., pages 1941-1947 (2000)). Dissolution of drug was determined in simulated gastric fluid without enzymes (SGF) or in simulated intestinal fluid Swithout enzymes (SIF) as described previously pages S2053, 4082 and 4680). The amount of drug released into SGF or SIF was determined by C18 reverse-phase high CA( pressure liquid chromatography.
The 6% and 8% Film Coated MPCs demonstrated o little difference in drug release in SGF or SIF (Figure (C1 The islvaleramide release profile of and 8% Film C-i Coated MPCs were similar to the Formulation II release Cy profile of 80% isovaleramide released in 16 hours (Figure Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention, which is defined by the claims below.
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
H: \marieag\Keep\Speci\P57359div.dc22/06/0s
Claims (10)
- 2. A composition according to claim 1, wherein said composition releases said active compound at a rate sufficient to maintain a therapeutically effective serum concentration of said active compound for at least 8 hours.
- 3. A composition according to claim i, wherein said composition releases said active compound at a rate sufficient to maintain a therapeutically effective serum concentration of said active compound for at least 12 hours.
- 4. A composition according to claim 5, wherein said gelling agent is xanthan gum. A composition according to any one of the proceeding claims, further comprising one or more excipients.
- 6. A composition according to any one of the preceding claims, wherein said formulation has a film- coating that retards access of liquids to the active compound and/or retards release of the active compound through the film-coating. H: \marieag\Keep\Speci\P57359div.doc22/06bo5
- 7. A composition according to claim 6, wherein said film coating comprises a polymeric coating material. (C 8. A composition according to claim 7, wherein said polymeric coating material comprises a mixture of ethyl cellulose and hydroxypropyl methylcellulose. 00 Cy 9. A composition according to claim 7 or 8, wherein Cg said polymeric coating material further comprises a placticizer. A composition according to any one of the preceding claims, wherein the composition is in the form of a tablet, capsule, or multiparticulate composition.
- 11. A process for preparing an oral sustained-release pharmaceutical composition comprising a matrix comprising a therapeutically effective amount of an active compound, and a gelling agent, and optionally one or more substances that further retards the release of the active compound, comprising: mixing together a therapeutically effective amount of an active compound with a gelling agent and optionally one or more substances that further retards the release of the active compound, and compressing or extruding said active compound, gelling agent, and optional substances that act to sustain release of the active compound, wherein the amount of said active compound represents about 40-70% by weight of the composition, and wherein the active compound is isovaleramide.
- 12. A process according to claim 11, wherein said 46 H:\marieag\Keep\Speci\P57359div.doc22/06/o5 matrix comprises xanthan gum. Z 13. A process according to claim 11 or 12, further (Ni comprising the step of coating the core matrix with a polymer solution to form a film-coating. 00 C 14. A method of treating a pathology that is C ameliorated by a modulation of CNS activity, wherein said C pathology is selected from the group consisting of V) 10 convulsions, spasticity, affective mood disorder, Sneuropathic pain syndrome, headache, restlessness syndrome, movement disorder substance abuse/craving, and cerebral trauma, comprising administering to a patient suffering from said pathology an oral sustained-release pharmaceutical composition, comprising a matrix comprising a therapeutically effective amount of an active compound; and a gelling agent, wherein the amount of active compound represents about 70% by weight of the composition, and wherein said active compound is isovaleramide. A method according to claim 14, wherein said sustained-release pharmaceutical composition is in tablet form and the tablet contains a therapeutically effective unit dose of the active compound.
- 16. A method according to claim 14, wherein said sustained-release pharmaceutical composition is a multiparticulate composition and the multiparticulate composition contains a therapeutically effective unit does of the active compound.
- 17. A method according to any one of claims 14 to 16, wherein said gelling agent comprises xanthan gum.
- 18. A method according to any one of claims 14 to 17, 47 H:\marieag\Keep\Speci\P57359div.doc22/o6/o5 wherein said composition further comprises a film-coating (N Scomprising a polymeric coating material. Dated this 22nd day of June, 2005 NPS PHARMACEUTICALS, INC. 00 C( By their Patent Attorneys Cq GRIFFITH HACK C- Fellows Institute of Patent and Trade Mark Attorneys of Australia 48 H: \marieag\Keep\Speci\P57359div.do22/06/o5
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005202728A AU2005202728A1 (en) | 1999-10-19 | 2005-06-22 | Sustained-release formulations for treating CNS-mediated disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16021099P | 1999-10-19 | 1999-10-19 | |
US60/160210 | 1999-10-19 | ||
PCT/US2000/041267 WO2001028516A2 (en) | 1999-10-19 | 2000-10-19 | Sustained-release formulations for treating cns-mediated disorders |
AU2005202728A AU2005202728A1 (en) | 1999-10-19 | 2005-06-22 | Sustained-release formulations for treating CNS-mediated disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU19695/01A Division AU780505B2 (en) | 1999-10-19 | 2000-10-19 | Sustained-release formulations for treating CNS-mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2005202728A1 true AU2005202728A1 (en) | 2005-07-21 |
Family
ID=34750803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005202728A Abandoned AU2005202728A1 (en) | 1999-10-19 | 2005-06-22 | Sustained-release formulations for treating CNS-mediated disorders |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2005202728A1 (en) |
-
2005
- 2005-06-22 AU AU2005202728A patent/AU2005202728A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100280099B1 (en) | Release Initiation Control and Release Rate Controlled Formulations | |
US8007827B2 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
AU781058B2 (en) | Delayed-action form of administration containing tramadol saccharinate | |
ES2606463T3 (en) | Combination of levodopa / carbidopa immediate release and controlled release dosage forms | |
EP2217217B1 (en) | Controlled release pharmaceutical compositions of pregabalin | |
KR0140492B1 (en) | Opioid formulations having extended controlled release | |
US10888521B2 (en) | Sustained release compositions using wax-like materials | |
KR100371523B1 (en) | Sustained-release theophylline tablet | |
JP6359022B2 (en) | Pharmaceutical composition comprising hydromorphone and naloxone | |
JPH0759500B2 (en) | Diffusion coated composite unit dose | |
KR20160045728A (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
JP6846343B2 (en) | Methods and compositions for the treatment of attention deficit disorder in particular | |
JP2004521910A (en) | Tramadol | |
AU2010258345A1 (en) | Novel pharmaceutical compositions containing pregabalin | |
US20150164920A1 (en) | Controlled release formulation comprising mesalamine | |
US7235258B1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
AU2018357350B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
AU780505B2 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
US20210290557A1 (en) | Multi-particulate pharmaceutical composition, immediate release pellets, sustained release pellets, enteric release pellets and use thereof | |
AU2005202728A1 (en) | Sustained-release formulations for treating CNS-mediated disorders | |
US8962020B2 (en) | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |